PETRI DISH PERSPECTIVES

Manead Khin

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives

  1. 2d ago

    Episode 82: Dr. Natalie Ma on Building Virtual Humans to Predict Drug Safety

    Send us Fan Mail After earning a PhD in molecular biology at Yale, Dr. Natalie Ma moved from the bench to the business side of science to tackle drug development’s biggest problem: roughly 90% of programs fail, often after years and millions of dollars. As co-founder and Chief Business Officer of Deep Origin, she helps build computational models that span the quantum mechanical to the whole human body. The goal is to predict drug safety before a molecule reaches an animal or a patient. Deep Origin also leads an eight-company ARPA-H consortium building a Virtual Human Avatar of Toxicology. In this episode, Dr. Ma unpacks why drug development has a prediction problem rather than a speed problem, how animal models and new approach methodologies (NAMs) can work together, and where AI in drug discovery is overhyped versus underrated. She also shares what pharma says it wants from AI versus what it actually buys, and what PhD founders need to know about the business side. Check out Deep Origin: https://deeporigin.com/ 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #AIDrugDiscovery #DrugDiscovery #DrugSafety #Toxicology #NAMs #VirtualHuman #ComputationalBiology #AIinHealthcare #Biotech #HealthTech #WomenInSTEM #DeepOrigin Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  2. Nov 12

    Episode 81: Mithril Medicine (Now Anthropic)

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Mithril Medicine, the one-person biotech that Anthropic just acquired and the story behind the man who built it. Cody Tranbarger spent six years posting anonymously on biotech X as “Professor Oak,” built a reputation in the crossover investing world without ever revealing his name, and then founded Mithril with Atlas Venture, one full-time employee (himself), and Claude running operations across 11 external laboratories. He called it "Pipeline-in-a-Person". We break down the science behind Mithril’s bispecific antibody program, a molecular clamp designed to bridge failing muscle fibers to the surrounding matrix in children with LAMA2-related congenital muscular dystrophy and alpha-dystroglycanopathy, two of the rarest and most devastating muscle diseases with no approved treatments. We get into the mouse data showing 2x grip strength gains, the six Claude errors that propagated into real lab experiments, and how a single April 2026 post triggered the conversations that led to an acquisition. We also zoom out to ask the bigger question: why is an AI safety company buying drug companies? We dig into Dario Amodei’s vision of AI curing most diseases within a decade, the Coefficient Bio acquisition that set the stage, and the conflict-of-interest questions the pharma industry hasn’t answered yet. This is a story about what happens when AI moves from tool to teammate to co-founder and what it means for the future of drug development. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #MithrilMedicine #AIinDrugDiscovery #RareDisease #LAMA2 #PipelineInAPerson #Anthropic #BiotechNews #DrugDiscovery #LifeSciences #BiotechInnovation #AIBiotech #PharmaNews #HealthcareInnovation Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  3. Nov 1

    October 2026: Biotech & Pharma NEWS Roundup

    Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for October 2026! This month was defined by a wave of oncology approvals, a head-to-head data drop that reshuffled the GLP-1 race, and M&A activity that shows Big Pharma is quietly pivoting away from oncology toward rare disease, pain, and RNA therapeutics. The FDA approved dostarlimab in locally advanced rectal cancer, tucatinib in HER2-positive breast cancer, and talazoparib plus enzalutamide in metastatic prostate cancer — three meaningful wins for patients in a single month. Lilly’s retatrutide beat Ozempic head-to-head with 20.9% weight loss in diabetic patients, cementing its status as the next major GLP-1 contender. On the deal front, Shionogi paid $2 billion for IntraBio in rare neurodegeneration, Viatris acquired Pacira BioSciences for $1.65 billion in non-opioid pain, and Merck KGaA bought Silence Therapeutics at a 130% premium — six deals totaling over $7 billion for the month. VC finished strong with Formation Bio raising $600 million to buy drug candidates and Dren Bio closing $350 million, part of over $1.4 billion in rounds in the final week alone. And HHS greenlighted six experimental peptides over the open objections of FDA career scientists — a regulatory move that signals growing tension between evidence standards and the current policy posture. The bigger story: capital is flowing, but it’s getting selective — and the therapeutic areas winning M&A attention this month tell you exactly where the smart money thinks the next decade of returns will come from. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  4. Oct 29

    Episode 79: Endeavor Health

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Endeavor Health, the Chicago-area hospital system most Illinoisans have driven past but couldn’t name. Born from Evanston Hospital in 1891, grown into NorthShore University HealthSystem, expanded through a 2022 merger with Edward-Elmhurst Health, and rebranded as Endeavor Health in December 2023, this is a system that has been quietly becoming one of the largest in the state. We break down Endeavor’s origins, its nine-hospital suburban footprint, the NorthShore Research Institute, and the financial reality of running a $6.4 billion system at near-zero operating margin and why that made what happened next almost inevitable. On October 14th, 2026, Endeavor and Rush University System for Health announced a proposed merger that would create a $10 billion combined system with 12 hospitals, 400+ care sites, 46,000 employees and clinicians, and over 2 million patients a year. We get into the deal mechanics, the leadership shake-up, the $1 billion endowment investment, and what nurses, patients, and healthcare economists are already pushing back on. This is a story about scale, survival, and what happens when a fragmented market finally stops pretending consolidation isn’t coming. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #EndeavorHealth #Rush #ChicagoHealthcare #HospitalMerger #HealthcareConsolidation #NorthShore #EdwardElmhurst #RushUniversity #HealthPolicy #HealthcareNews #LifeSciences #Healthcare #HealthcareLeadership #BiotechNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

  5. Oct 15

    Episode 77: Revolution Medicines

    Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Revolution Medicines, the precision oncology company that spent over a decade trying to drug one of cancer’s most notorious targets: RAS. With mutations present in roughly 30% of all new cancer diagnoses, including pancreatic, lung, and colorectal cancers, RAS has long been considered undruggable. Revolution bet their entire company on proving that wrong. We break down the science behind their tricomplex inhibitor platform, the three lead drugs in their pipeline, daraxonrasib, elironrasib, and zoldonrasib, and the landmark Phase 3 RASolute 302 results that showed unprecedented overall survival in metastatic pancreatic cancer, earned a Plenary presentation at ASCO 2026, and triggered an FDA NDA review. But this is also a story about the pressure of building an ambitious company with no revenue, nearly $1 billion in annual R&D spend, and a failed $30 billion acquisition attempt with Merck that sent the stock crashing 26% in a single day. Revolution walked away from the deal. The question now is whether that confidence was prescient or premature. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #RevolutionMedicines #RAS #KRAS #Oncology #PancreaticCancer #LungCancer #Daraxonrasib #Biotech #DrugDiscovery #PrecisionOncology #CancerResearch #FDA #LifeSciences #Healthcare #BiotechTok #BiotechNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

About

Burma | ChicagoScientist 🥼🧪🔬Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎 Stream new episodes every THURSDAY! https://linktr.ee/maneadkhin #biotech #pharma #healthcare #podcast #petridishperspectives